Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionHealthCor Management, L.P.
Latest Disclosed Ownership20,000 shares
Latest Disclosed Value $ 2,388,800
HealthCor Management, L.P. ownership in NBIX / Neurocrine Biosciences, Inc.

On February 15, 2023 - HealthCor Management, L.P. filed a 13F-HR form disclosing ownership of 20,000 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $2,388,800 USD as of December 31, 2022. The entity filed a previous 13F-HR on November 14, 2022 disclosing 21,720 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of -7.92% during the quarter. The current value of the position is $3,277,600 USD.

HealthCor Management, L.P. has a history of taking positions in derivatives of the underlying security (NBIX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

NBIX / Neurocrine Biosciences, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2023-02-15 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 20,000 -1,720 -7.92 2,389 3.51 2.1893
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,720 21,720 2,307 0.2885
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -23,480 -100.00 0 -100.00
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 23,480 -342,257 -93.58 2,201 -92.93 0.1468
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 365,737 -80,002 -17.95 31,150 -27.14 1.6951
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 445,739 55,759 14.30 42,751 12.64 1.8447
2021-08-16 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 389,980 389,980 37,953 1.5171
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -226,460 -100.00 0 -100.00
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 226,460 -700,610 -75.57 21,706 -75.65 0.8371
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 927,070 571,300 160.58 89,147 105.39 3.5678
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 355,770 -1,191,970 -77.01 43,404 -67.60 1.8184
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,547,740 740,876 91.82 133,957 54.45 5.7253
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 806,864 -686,616 -45.97 86,730 -35.55 3.0941
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,493,480 -877,910 -37.02 134,577 -32.78 5.0869
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,371,390 855,300 56.41 200,216 49.90 7.7683
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,516,090 747,460 97.25 133,568 143.35 5.3961
2019-02-14 2018-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 768,630 358,274 87.31 54,888 8.79 1.7158
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 793,955 77,998
2018-11-15 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 410,356 -383,599 -48.31 50,453 -35.32 1.6732
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 793,955 102,360 14.80 77,998 35.99 2.4766
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 691,595 -833,405 -54.65 57,354 -51.53 1.9505
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,525,000 -562,110 -26.93 118,325 -7.48 3.8511
2017-11-14 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,087,110 -463,068 -18.16 127,898 9.03 4.2859
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,550,178 1,325,178 108.18 117,308 121.16 4.2332
2017-05-15 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 1,225,000 236,100 23.88 53,043 38.60 2.4335
2017-02-14 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 988,900 988,900 -19.27 38,270 -27.85 2.1627
2016-11-14 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -450,000 -100.00 0 -100.00
2016-08-15 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 450,000 -275,000 -37.93 20,453 -28.67 1.1155
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 725,000 725,000 61.11 28,674 40.19 1.6246
2016-02-16 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -150,000 -100.00 0 -100.00
2015-11-16 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 150,000 150,000 5,969 0.3360
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2016-11-14 2016-09-30 13F NEUROCRINE BIOSCIENCES COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2016-08-15 2016-06-30 13F NEUROCRINE BIOSCIENCES COM Call 310,000 14,090 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.